USPTO Examiner CHONG KIMBERLY - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19233142COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13AJune 2025December 2025Allow610YesNo
19070094COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13AMarch 2025November 2025Allow911YesNo
19054315CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USEFebruary 2025March 2026Allow1330NoNo
19054728TRANSLATION ENHANCING NUCLEIC ACID COMPOUNDS: ASO COUPLED TRANSLATION – UPREGULATION 1 (ACT-UP1) AND USES THEREOFFebruary 2025January 2026Allow1221NoNo
19052052Methods and Compositions for Treatment of Polycystic Kidney DiseaseFebruary 2025November 2025Allow911NoNo
19010571SMALL RNA-BASED DRUG, PREPARATION AND USE THEREOF IN PROPHYLAXIS AND/OR TREATMENT OF CARDIOMYOPATHYJanuary 2025September 2025Allow921NoNo
18797394TREATMENT OF MST1 RELATED DISEASES AND DISORDERSAugust 2024March 2025Allow711NoNo
18660147COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYMay 2024September 2025Allow1731YesNo
18594132COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFMarch 2024October 2024Allow820NoNo
18429059ASSAYS AND METHODS TO ASSIST IN VITRO FERTILIZATIONJanuary 2024September 2025Allow1941YesNo
18410136NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERYJanuary 2024May 2024Allow410NoNo
18543966COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOFDecember 2023February 2025Abandon1421NoNo
18449850TARGETED TRANS-SPLICING USING CRISPR/CAS13August 2023January 2025Allow1722YesNo
18362190RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISJuly 2023February 2026Allow3120NoNo
18330590NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERYJune 2023March 2026Abandon3320NoNo
18202328POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOFMay 2023October 2025Abandon2901NoNo
18301040MICRORNAS AND METHODS OF THEIR USEApril 2023October 2025Abandon3001NoNo
18178841Oligonucleotide Comprising Inosine for Treating DMDMarch 2023May 2025Abandon2601NoNo
18179325NEURODEGENERATIVE DISORDERSMarch 2023January 2026Allow3421YesNo
18174793METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASEFebruary 2023May 2025Abandon2710NoNo
18163506NUCLEIC ACID COMPLEXFebruary 2023February 2026Abandon3711NoNo
18156360RNA Interactome of Polycomb Repressive Complex 1 (PRC1)January 2023August 2025Abandon3111NoNo
18152504SINGLE-STRANDED OLIGONUCLEOTIDEJanuary 2023January 2026Abandon3611YesNo
18147549REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPYDecember 2022June 2025Abandon3010NoNo
18145604ANTISENSE OLIGOMER COMPOUNDSDecember 2022April 2025Abandon2710NoNo
18086209SIRT1-saRNA Compositions and Methods of UseDecember 2022June 2025Abandon3001NoNo
18065086SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATIONDecember 2022July 2025Allow3111NoNo
18056382Nucleic Acid Compounds for Binding Growth Differentiation Factor 11November 2022May 2025Abandon2901NoNo
18056664COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHYNovember 2022December 2024Allow2520NoNo
17986023METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL)November 2022January 2026Abandon3801NoNo
17984486SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONSNovember 2022July 2025Allow3321NoNo
18053447Modulators of APOL1 ExpressionNovember 2022August 2024Allow2110NoNo
18053559TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHYNovember 2022July 2025Allow3211NoNo
17970887COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSIONOctober 2022September 2025Allow3521YesNo
18047973COMPOUNDS AND METHODS FOR MODULATING ATXN1October 2022August 2024Allow2210NoNo
17936820MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROMESeptember 2022June 2025Allow3221NoNo
17931659Novel System for the Biocontrol of White Spot Syndrome Virus (WSSV) in AquacultureSeptember 2022July 2024Allow2210NoNo
17910574GENE REPLACEMENT THERAPY FOR FOXG1 SYNDROMESeptember 2022August 2025Allow3510NoNo
17908199ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF USHER SYNDROMEAugust 2022December 2025Abandon3910NoNo
17898947COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOFAugust 2022November 2025Allow3821NoNo
17822511LYOPHILIZATION OF RNAAugust 2022September 2024Allow2411NoNo
17822342COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHYAugust 2022December 2025Allow4031NoNo
17818879STABILIZED HNF4A SARNA COMPOSITIONS AND METHODS OF USEAugust 2022May 2025Abandon3311NoNo
17876881CHANNEL MODULATORSJuly 2022December 2025Allow4021YesNo
17815493ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOFJuly 2022August 2024Allow2410NoNo
17867929METHODS RELATING TO LUNG CANCERJuly 2022April 2025Allow3221YesYes
17813249Modulation of Huntingtin ExpressionJuly 2022January 2025Allow3021NoNo
17811808DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNAJuly 2022September 2024Allow2611NoNo
17810495CIRCULATING MICRORNA SIGNATURES FOR OVARIAN CANCERJuly 2022April 2025Allow3321YesNo
17789750ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF NEUROLOGICAL DISORDERSJune 2022January 2026Abandon4201NoNo
17788826ANTISENSE NUCLEIC ACID THAT INDUCES SKIPPING OF EXON 50June 2022November 2025Abandon4110YesNo
17843657PRODUCTS AND COMPOSITIONSJune 2022December 2025Abandon4241NoNo
17842478OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITYJune 2022January 2025Allow3121NoNo
17840152CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASJune 2022March 2025Abandon3321NoNo
17442663DOUBLE-STRANDED NUCLEIC ACID COMPLEX AND USE THEREOFMay 2022January 2026Abandon5201NoNo
17778567METHODS AND COMPOSITIONS FOR NEUROPROTECTIONMay 2022December 2025Allow4311NoNo
17749039Immunomodulatory RNAMay 2022November 2025Allow4221YesNo
17743663Modified RNA Agents with Reduced Off-Target EffectMay 2022October 2024Allow2921NoNo
17755943IL-34 ANTISENSE AGENTS AND METHODS OF USING SAMEMay 2022November 2025Abandon4201NoNo
17738987METHOD FOR DELIVERING RNA TO NEURONS TO TREAT HERPES INFECTIONSMay 2022July 2024Allow2611NoNo
17721530COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFApril 2022March 2025Allow3511NoNo
17719019Adeno-Associated Virus Vector Delivery of Microrna-29 to Treat Muscular DystrophyApril 2022August 2025Abandon4030YesNo
17697577Modified Compounds and Uses ThereofMarch 2022September 2024Allow3011NoNo
17693120TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTRMarch 2022August 2024Allow3020NoNo
17676586DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNAFebruary 2022March 2024Allow2510YesNo
17675800TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERSFebruary 2022July 2024Allow2911YesNo
17635190A Method Of Promoting Survival And/Or Function Of A Motor Neuron And Related Agents, Uses And MethodsFebruary 2022February 2026Allow4821NoNo
17667094MODULATORS OF MALAT1 EXPRESSIONFebruary 2022August 2024Allow3021NoNo
17665348COMPOUNDS AND METHODS FOR MODULATING C90RF72February 2022January 2025Abandon3511NoNo
17631654CONJUGATE AND USES THEREOFJanuary 2022February 2026Allow4911NoNo
17581855OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSIONJanuary 2022March 2024Allow2611NoNo
17576245Compounds and Methods for Modulating UBE3A-ATSJanuary 2022June 2024Allow2911NoNo
17626981MELANOPHILIN ANTISENSE OLIGONUCLEOTIDESJanuary 2022October 2025Abandon4501NoNo
17596764COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAiDecember 2021August 2025Abandon4401NoNo
17618801TREATMENT OF HEART FAILURE IN HUMAN SUBJECTSDecember 2021January 2026Allow4911NoNo
17537195BI SPECIFIC APTAMERNovember 2021July 2024Allow3221NoNo
17524323NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELLNovember 2021June 2025Abandon4311YesNo
17523030CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021April 2025Allow4122YesNo
17498880ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODSOctober 2021June 2024Allow3211NoNo
17478219THERAPEUTIC COMPOSITIONS FOR TREATING PAIN VIA MULTIPLE TARGETSSeptember 2021July 2024Allow3421NoNo
17474765CONJUGATION OF LIPOPHILIC ALBUMIN-BINDING MOIETY TO RNA FOR IMPROVED CARRIER-FREE IN VIVO PHARMACOKINETICS AND GENE SILENCINGSeptember 2021September 2024Allow3621NoNo
17436254MULTIMERIC OLIGONUCLEOTIDES WITH ENHANCED BIOACTIVITYSeptember 2021January 2025Abandon4011YesNo
17411460Treatment Of Sepsis With PCSK9 And LDLR ModulatorsAugust 2021March 2025Allow4311YesNo
17305225MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCEJuly 2021December 2024Allow4131NoNo
17364765NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOFJune 2021March 2025Allow4541NoNo
17359196ENHANCED OLIGONUCLEOTIDES FOR MODULATING FUBP1 EXPRESSIONJune 2021December 2025Allow5441YesNo
17323826METHODS FOR REDUCING ATAXIN-2 EXPRESSIONMay 2021August 2024Allow3921YesNo
17320139OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULINMay 2021September 2024Allow4042YesNo
17293452ASPARAGINASE THERAPEUTIC METHODSMay 2021September 2025Abandon5221NoNo
17284310DETECTING CANCER CELL OF ORIGINApril 2021March 2025Abandon4711NoNo
17280411Treating Atopic Dermatitis by Targeting the WNT PathwayMarch 2021September 2025Allow5421YesNo
17204483OLIGONUCLEOTIDES FOR SNCA MODULATIONMarch 2021March 2024Allow3621NoYes
17271496COMPOSITIONS AND METHODS FOR DETECTING ANTIBIOTIC RESPONSIVE mRNA EXPRESSION SIGNATURES AND USES THEREOFFebruary 2021June 2025Allow5221NoNo
17181870MULTI-TARGETED SINGLE ENTITY CONJUGATESFebruary 2021September 2024Allow4331YesNo
16982758BBB-CROSSING LIPID LIGAND OF HETERO NUCLEIC ACIDFebruary 2021January 2025Allow5221YesNo
17144456EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATIONJanuary 2021August 2024Allow4321NoNo
17129463PLANT VIRAL RNA DELIVERY NANOPARTICLES AND USES THEREOFDecember 2020September 2024Allow4541NoNo
17055710MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECTNovember 2020September 2024Allow4511NoNo
17054724OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDESNovember 2020December 2024Abandon4922NoNo
17090804DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE - IINovember 2020June 2025Allow5531NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, KIMBERLY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
2
(28.6%)
Examiner Reversed
5
(71.4%)
Reversal Percentile
88.4%
Higher than average

What This Means

With a 71.4% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
10
(37.0%)
Not Allowed After Appeal Filing
17
(63.0%)
Filing Benefit Percentile
60.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHONG, KIMBERLY - Prosecution Strategy Guide

Executive Summary

Examiner CHONG, KIMBERLY works in Art Unit 1636 and has examined 213 patent applications in our dataset. With an allowance rate of 94.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner CHONG, KIMBERLY's allowance rate of 94.8% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHONG, KIMBERLY receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHONG, KIMBERLY is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +5.3% benefit to allowance rate for applications examined by CHONG, KIMBERLY. This interview benefit is in the 31% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.2% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.5% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 69.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.7% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.9% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.